Cardinal Health has drawn fresh attention after releasing its fourth quarter and full year 2026 results, paired with a new US$5b share repurchase authorization and a confirmed quarterly dividend. The latest numbers give an updated view of how the healthcare distributor is converting its large revenue base into profit and cash flow, and show how management is choosing to return capital to shareholders through buybacks and regular dividends. The earnings, dividend affirmation and expanded buyback program come after a strong run in the stock, with a 90 day share price return of 17.07% and a 5 year total shareholder return of 405.81%. Cardinal Health's most followed narrative sees fair value at $264.73 per share compared with the last close at $234.85, which puts the spotlight on the assumptions behind that gap. However, the current P/E of 31.9x is above both peers at 26.2x and the US Healthcare industry at 25x, raising the question of whether the stock represents a clear bargain or simply reflects fairly full pricing with limited margin for error.
Cardinal Health IncQ4 results, $5B buyback, and dividend confirmation are positive capital allocation news.
